Results 151 to 160 of about 5,401 (177)

Vismodegib

Reactions Weekly, 2018
Vismodegib (GDC-0449, Erivedge®) is a small molecule antagonist of the hedgehog (Hh) pathway that binds to smoothened (SMO) and leads to inhibition of an aberrant activation of the Hh pathway. Dysregulated Hh signaling results in uncontrolled proliferation in basal cell carcinoma (BCC) and has also been found present in medulloblastoma, and many other ...
Meiss, Frank, Andrlova, Hana, Zeiser, Robert   +2 more
  +8 more sources

Vismodegib

Reactions Weekly, 2019
  +10 more sources

Vismodegib

Reactions Weekly, 2022
openaire   +2 more sources

Vismodegib

Reactions Weekly, 2015
  +7 more sources

Vismodegib

Reactions Weekly, 2021
openaire   +2 more sources

Vismodegib

Reactions Weekly
  +5 more sources

Vismodegib

Reactions Weekly, 2013
openaire   +1 more source

Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial

European Journal of Cancer, 2017
N Basset-Séguin, Axel Hauschild, Laurent Mortier   +2 more
exaly  

Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects

British Journal of Clinical Pharmacology, 2012
Richard A Graham, Cornelis E C A Hop, Young G Shin   +2 more
exaly  

Vismodegib, an antagonist of hedgehog signaling, directly alters taste molecular signaling in taste buds

Cancer Medicine, 2015
Wei-Na Cong, Jeong Seon Yoon, Josephine M Egan   +2 more
exaly